Jade Biosciences

JBIO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Jade Biosciences, Inc. is a biotechnology company focused on therapies for inflammation and immunology in autoimmune diseases. Its lead asset, JADE101, is a monoclonal antibody that inhibits the APRIL ligand and is in a Phase 1 trial. The company is also developing JADE201 and JADE-003 in preclinical stages. Jade has a collaboration with Paragon Therapeutics and is based in Waltham, Massachusetts.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive